TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Clinical trial NCT06323525 · RECRUITING
Trial details
- NCT number
- NCT06323525
- Sponsor
- Chinese PLA General Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-17
- Primary completion
- 2026-04-25
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.